ProMab Biotechnologies has been dedicated from the first day to develop monoclonal antibodies of the highest quality.We have invested in the recombinant antibody technology to effectively immortalize the best hybridoma clones. This has given us the ability to extend our antibody engineering capabilities, including the generation of bispecific antibodies.
Included in Custom Package
- scFv Validation
- Production of a recombinant antibody library
- Sequence information for both the Heavy and Light chains
- Delivery of stable expression plasmid
Starting at $14,500
We know how to generate an antibody that is specific to the immunizing antigen and that works for the intended application.
To decrease the immunogenicity of monoclonal antibodies derived from rodents, ProMab Biotechnologies uses a rational approach based on antibody sequence and 3D structure by computer modeling and docking programs. In brief, steps include: hybridoma sequencing, analysis of the scFv by different bioinformatics and computer programs, generating best models and retesting humanized scFvs in a CAR-T setting.
We provide comprehensive tools for scFv validation in vitro. The scFv validation platform contains an antigen/cell binding assay, a cell killing assay, and a cytokine induction assay. Our tools include 1) 42 DNA fingerprint-certified authenticated cell lines; 2) 8,000 tissue blocks - 5000 from diseased tissues, 3000 from normal tissues; 3) >30 types of primary cells. All of these can be used for antigen expression profiling to improve the CAR-T therapeutic index.
This is done by a group of bioinformaticists and antibody engineering experts with many years of experience in antibody humanization with references below.
1. Alexey Teplyakov, Galina Obmolova, Thomas J. Malia, Jinquan Luo, Salman Muzammil, Raymond Sweet, Juan Carlos Almagro & Gary L. Gilliland. Structural diversity in a human antibody germline library. mAbs. V9, 2016, 1045-63.
2. Almagro J.C., Teplyakov A., Luo J., Sweet R.W, Kodangattil S, hernandez-Guzman F, Gilliand G.L. Second antibody modeling assessment (AMA-II). Proteins 2014; 82: 1553-1562.
3. Almagro JC, Fransson J. Humanization of antibodies. Front Biosci., 2008, 1;13:1619-33.